HDAC9 and diffuse large B-cell lymphoma: Recently, a class I HDAC inhibitor called nanatinostat has moved through a phase I/IIb clinical trial for treatment of multiple EBV-associated lymphomas including DLBCL, Hodgkin’s lymphomas, and NK/T cell lymphomas [7, 26].